Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Avacta Sign Third Distribution Agreement with Pall Life Sciences

Published: Friday, September 28, 2012
Last Updated: Friday, September 28, 2012
Bookmark and Share
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech market.

Avacta Analytical has signed a third distribution agreement with Pall Life Sciences - appointing Pall as the Indian distributor for its market-leading Optim 1000 protein drug development tool.

The Optim 1000 is an innovative analytical instrument that provides biopharmaceutical developers with information about the viability of candidate drug molecules and formulations much earlier in the drug development process, avoiding costly end stage product failures.

The latest collaboration extends the existing North America and South East Asia agreements, granting Pall exclusive marketing and distribution rights to the Optim 1000, to include India.

Alastair Smith, Chief Executive of Avacta Group, commented: “Pall has proved an excellent partner for Avacta, and the success of our existing collaborations in North America and South East Asia was a major factor in the decision to appoint the Company as the sole distributor for the Optim 1000 in India. The Indian biopharma industry is growing rapidly, offering exciting new opportunities, and we look forward to working with Pall in this new territory.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Avacta Analytical Partners with UCL
Avacta Analytical is partnering with University College London (UCL) as an industrial sponsor of the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies.
Friday, November 18, 2011
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
First 3-D Vision of Cancer Target
This basic research set the grounds for structure-based drug design approaches that could be beneficial for cancer treatments' - Dr. Cyril Dominguez, University of Leicester.
New Light Shed on Genetic Regulation
A team of scientists has uncovered greater intricacy in protein signaling than was previously understood, shedding new light on the nature of genetic production.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!